Velasco Cimica, Ph.D., is an expert in vaccine development using virus-like particles for developing vaccine candidates for emerging viruses. Join this webinar to hear Dr. Cimica cover the following key points:

  • ATCC has developed a POW-VLP–based vaccine candidate that delivers a specific antigen against the virus.
  • POW-VLP induced a strong antibody response against the POWV, affording 100% seroconversion in a mouse model. 
  • Antibody response elicited by POW-VLP immunization showed a high level of neutralization activity against POWV.

Kevin Tyo, PhD, and Kevin Grady, BS, are adept at developing cell-based assays that incorporate immortalized primary cells. Join this webinar to hear Dr. Tyo and Mr. Grady cover these topics:

  • hTERT-immortalized primary cells are comparable to primary cells regarding physiological relevance, but are able to avoid replicative senescence.
  • Using well-characterized hTERT-immortalized cells, ATCC has created credible cell models for toxicological studies on the kidney, skin, and airway.
  • Our data show that these modified primary cells are effective tools that provide tissue-relevant results and reproducibility for any cell-based assay, including toxicology assays.

In this webinar ATCC bioinformatician Briana Benton discusses the reference-quality microbial genomes with corresponding metadata that are now publicly available to the scientific community on the ATCC Genome Portal ( This webinar will cover these key takeaways:

  • Discuss why ATCC is committed to providing reference-quality genomes for items within the microbial collections
  • Understand the standardized process and quality control criteria required for growing, extracting, sequencing, and analyzing each reference-quality genome
  • Explore the features of the ATCC Genome Portal

Steve Budd, MBA, has extensive experience developing advanced models such as organoids. Watch this webinar to hear this ATCC expert cover the following key points:

  • Clinical and sequencing data for the HCMI models are available through a linked portal to the HCMI searchable catalog and the GDC data portal.
  • While 3D organoid culture may seem intimidating, careful preparation and good work instructions, such as those contained in this webinar, will start you on the path to successfully culturing this advanced type of in vitro model.
  • ATCC further supports the HCMI models by offering organoid "CoreKits" that contain the necessary reagents for organoid expansion.

Dr. Elizabeth Gillies is well-versed in using CRISPR/Cas9 genome-editing technology for creating advanced cell-based models. Watch the presentation to learn how this cutting edge technology was used to enhance virus production in ATCC cell lines, and stay for a lively question and answer session. ATCC's Dr. Fang Tian will be joining us to answer your questions about this breakthrough in virus production.

  • Most viral vaccines are manufactured in large-scale tissue culture systems using historical cell lines that are approved for vaccine manufacturing.
  • ATCC used CRISPR/Cas9 gene-editing techniques to increase the viral production efficiency of some of these historical cell lines.
  • These enhanced virus-producing cell lines have the potential to significantly reduce the costs associated with generating viral vaccines and high-titer viral stocks.

Join top virologists Adria Allen, Alexander Piccirillo, and Megan Yockey for an in-depth look at viral propagation strategies used at ATCC. This webinar will cover these takeaways:

  • ATCC cultures viruses with several basic propagation types (e.g., lytic, cell-associated, persistently infected cells, egg propagation).  
  • Multiple tools and processes are used to optimize protocols, including multiplicity of infection (MOI) optimization. 
  • ATCC authenticates and tests each virus to make sure we are distributing the highest quality products to our customers. 
  • ATCC uses numerous strategies for troubleshooting (e.g., mycoplasma cleanup, failure to grow, adaptation to new host cells).

In this webinar Diversigen, Inc. scientist Dr. Tasha Santiago-Rodrigues will discuss the field of viral metagenomics, focusing on the following key points:

  • Implementation of viral standards and controls can help determine biases that could be potentially introduced at different stages of a viral metagenomics pipeline.
  • Identification of biases in a viral metagenomics study provides the opportunity to troubleshoot and benchmark reagents and analysis tools. 
  • Viral standards may evolve to mimic simple and more complex viral communities in diverse environments.

Steve Budd, MBA, has extensive experience with culturing hard-to-grow cell lines and primary cells. Watch this webinar to hear this ATCC expert cover the following key points:

  • There are many cell models; choosing the correct one for your workflow will add efficiency and productivity to your work.
  • When culturing specialty cells, such as stem cells or primary cells, certain considerations regarding the choice of media and reagents must be taken.
  • Using misidentified or cross-contaminated cell lines in experiments can invalidate experimental results; therefore, authenticating cell lines should be part of your cell culture workflow.
  • Mycoplasma infection can chronically affect the well-being of cells in culture without being detected by visual observation; multiple screening methods can be used to identify contamination.
  • Tools such as proliferation assays and cryo-containers can aid the maintenance of cell health.

In this webinar, ATCC experts Marco Riojas and Andrew Frank discuss the critical role that ATCC and BEI Resources play in providing front-line COVID-19 researchers with the high-quality authenticated biomaterials necessary to counter the current global threat and our own research efforts in the genomic analysis of SARS-CoV-2 and the subsequent publication of our genomic data on the ATCC Genome Portal. Watch the webinar to hear:

  • A description of ATCC and BEI Resources' wide range of SARS-CoV-2 standard material  
  • A study depicting how we sequence SARS-CoV-2 isolates for ATCC and BEI Resources
  • A recap of our efforts to reduce genomic variability in cultured SARS-CoV-2

In this webinar, ATCC biologist Brian Della Fera will present THP-1 luciferase reporter cell lines, a new tool for the development of immunomodulatory drugs and biologics. Attend this webinar to discover:

  • THP-1 cell line is a commonly used surrogate model for in vitro human primary monocytes
  • This luciferase reporter system provides a straightforward, robust, and sensitive means to measure biological processes through in vitro bioluminescence measurements
  • THP-1 luciferase reporter cell lines allow broad application in drug development, cell signaling pathway research, and as a safety evaluation tool for new chemicals and drugs